Your browser doesn't support javascript.
loading
IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy.
Krueger, James G; Eyerich, Kilian; Kuchroo, Vijay K; Ritchlin, Christopher T; Abreu, Maria T; Elloso, M Merle; Fourie, Anne; Fakharzadeh, Steven; Sherlock, Jonathan P; Yang, Ya-Wen; Cua, Daniel J; McInnes, Iain B.
Afiliación
  • Krueger JG; Laboratory for Investigative Dermatology, The Rockefeller University, New York, NY, United States.
  • Eyerich K; Department of Medicine, Division of Dermatology and Venereology, Karolinska Institute, Stockholm, Sweden.
  • Kuchroo VK; Department of Dermatology and Venereology, Medical Center, University of Freiburg, Freiburg, Germany.
  • Ritchlin CT; Evergrande Center for Immunologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.
  • Abreu MT; Allergy, Immunology & Rheumatology Division, Center for Musculoskeletal Research, University of Rochester Medical School, Rochester, NY, United States.
  • Elloso MM; Division of Gastroenterology, Department of Medicine, University of Miami Leonard Miller School of Medicine, Miami, FL, United States.
  • Fourie A; Janssen Scientific Affairs, LLC, Horsham, PA, United States.
  • Fakharzadeh S; Janssen Research & Development, LLC, San Diego, CA, United States.
  • Sherlock JP; Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, United States.
  • Yang YW; Janssen Research & Development, LLC, Spring House, PA, United States.
  • Cua DJ; Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom.
  • McInnes IB; Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, United States.
Front Immunol ; 15: 1331217, 2024.
Article en En | MEDLINE | ID: mdl-38686385
ABSTRACT
Interleukin (IL)-23, an IL-12 cytokine family member, is a hierarchically dominant regulatory cytokine in a cluster of immune-mediated inflammatory diseases (IMIDs), including psoriasis, psoriatic arthritis, and inflammatory bowel disease. We review IL-23 biology, IL-23 signaling in IMIDs, and the effect of IL-23 inhibition in treating these diseases. We propose studies to advance IL-23 biology and unravel differences in response to anti-IL-23 therapy. Experimental evidence generated from these investigations could establish a novel molecular ontology centered around IL-23-driven diseases, improve upon current approaches to treating IMIDs with IL-23 inhibition, and ultimately facilitate optimal identification of patients and, thereby, outcomes.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Interleucina-23 Límite: Animals / Humans Idioma: En Revista: Front Immunol Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Interleucina-23 Límite: Animals / Humans Idioma: En Revista: Front Immunol Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Suiza